StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) stock

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$286.01−6.81 (-2.33%)

Close on Nov 18, 2026Market cap $505.41BP/E 80.8Yield 2.33%

AbbVie net income

Net income is the profit left for shareholders after every expense, interest and tax.

AbbVie's net income for the twelve months ending Jun 30, 2026 was $6.31B, up 67.7% year over year. For fiscal 2025 it was $4.23B, down 1.2% from the year before. Over ten years it grew -1.9% a year on average. The highest annual figure on record is $11.84B in fiscal 2022.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.23B-1.2%
FY2024Dec 31, 2024$4.28B-12.0%
FY2023Dec 31, 2023$4.86B-58.9%
FY2022Dec 31, 2022$11.84B+2.5%
FY2021Dec 31, 2021$11.54B+150.0%
FY2020Dec 31, 2020$4.62B-41.4%
FY2019Dec 31, 2019$7.88B+38.6%
FY2018Dec 31, 2018$5.69B+7.1%
FY2017Dec 31, 2017$5.31B-10.8%
FY2016Dec 31, 2016$5.95B+15.7%
FY2015Dec 31, 2015$5.14B+190.0%
FY2014Dec 31, 2014$1.77B–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.61B+285.2%
Q1 FY2026Mar 31, 2026$695.00M-46.0%
Q4 FY2025Dec 31, 2025$1.82B–
Q3 FY2025Sep 30, 2025$186.00M-88.1%
Q2 FY2025Jun 30, 2025$938.00M-31.5%
Q1 FY2025Mar 31, 2025$1.29B-6.1%
Q4 FY2024Dec 31, 2024-$22.00M-102.7%
Q3 FY2024Sep 30, 2024$1.56B-12.2%
Q2 FY2024Jun 30, 2024$1.37B-32.3%
Q1 FY2024Mar 31, 2024$1.37B+472.8%
Q4 FY2023Dec 31, 2023$822.00M-66.8%
Q3 FY2023Sep 30, 2023$1.78B-55.0%
Q2 FY2023Jun 30, 2023$2.02B+119.0%
Q1 FY2023Mar 31, 2023$239.00M-94.7%
Q4 FY2022Dec 31, 2022$2.47B-38.8%
Q3 FY2022Sep 30, 2022$3.95B+24.2%
Q2 FY2022Jun 30, 2022$924.00M+20.6%
Q1 FY2022Mar 31, 2022$4.49B+26.4%
Q4 FY2021Dec 31, 2021$4.04B+11133.3%
Q3 FY2021Sep 30, 2021$3.18B+37.7%
Q2 FY2021Jun 30, 2021$766.00M–
Q1 FY2021Mar 31, 2021$3.55B+18.0%
Q4 FY2020Dec 31, 2020$36.00M-98.7%
Q3 FY2020Sep 30, 2020$2.31B+22.5%
Q2 FY2020Jun 30, 2020-$738.00M-199.6%
Q1 FY2020Mar 31, 2020$3.01B+22.6%
Q4 FY2019Dec 31, 2019$2.80B–
Q3 FY2019Sep 30, 2019$1.88B-31.4%
Q2 FY2019Jun 30, 2019$741.00M-62.6%
Q1 FY2019Mar 31, 2019$2.46B-11.7%
Q4 FY2018Dec 31, 2018-$1.83B-3611.5%
Q3 FY2018Sep 30, 2018$2.75B+68.4%
Q2 FY2018Jun 30, 2018$1.98B+3.6%
Q1 FY2018Mar 31, 2018$2.78B+62.7%
Q4 FY2017Dec 31, 2017$52.00M-96.3%
Q3 FY2017Sep 30, 2017$1.63B+2.1%
Q2 FY2017Jun 30, 2017$1.92B–
Q1 FY2017Mar 31, 2017$1.71B–
Q4 FY2016Dec 31, 2016$1.39B–
Q3 FY2016Sep 30, 2016$1.60B–

More AbbVie figures

See a number that looks wrong?